Laura Hogenboom

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Carla Rodriguez-Mogeda, Zoë YGJ van Lierop, Susanne M. A. van der Pol et al. · Journal of Neuroinflammation · 2023 · 36 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Ocrelizumab Concentration Is a Good Predictor of <scp>SARS‐CoV</scp>‐2 Vaccination Response in Patients with Multiple Sclerosis

Zoé L. E. van Kempen, Laura Hogenboom, Alyssa A Toorop et al. · Annals of Neurology · 2022 · 13 citations · Full text

Life Sciences, Immunology, Pharmacokinetics +17

Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis

Alyssa A Toorop, Laura Hogenboom, Karien Bloem et al. · Journal of Neurology Neurosurgery & Psychiatry · 2023 · 13 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic

Zoë YGJ van Lierop, Mark HJ Wessels, Womei ML Lekranty et al. · Multiple Sclerosis Journal · 2024 · 12 citations · Full text

Life Sciences, Neurology, Neuroscience +16